GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Modeyso® | ONC-201 | ONC201 | TIC-10 | TIC10
                                 
                                                         
                            
                            
                            
                                 
                                
                                dordaviprone is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Dordaviprone (ONC201, also known as TIC10 [2]) was originally discovered as a TRAIL pathway inducer and as an orally active dual Akt/ERK inhibitor [1]. It exerts potent anti-tumour effects [6,10-11]. 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                    ONC201 was later reported as an allosteric activator of the oncology drug target, mitochondrial protease caseinolytic protease P (ClpP) [4-5,9]. It also antagonises dopamine D2/3 receptor signalling [7-8].  | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||